The sales are trivial in size relative to market cap and involve the General Counsel and a non-C-suite insider. No material bearish signal. Monitor next insider cluster for larger dollar amounts or C-suite participation.
Drugs in focus
RCKT drug pipeline →KRESLADI
● Neutral Named in this insider cluster- Impact
- Phase
- Approved (FDA accelerated approval)
- Time to market
- Already FDA-approved (March 26, 2026); commercial launch underway
- Next catalyst
- None dated
What to watchKRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $2.30entry
- T+1 · 20h ago −6.09%α −4.18% · $2.16
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Rocket Pharmaceuticals sold a combined $139K in open-market sales within days of the Q3 2026 earnings release. The sales are small relative to the $272M market cap (0.05%) and are not under 10b5-1 plans, but the dollar amount is below the materiality threshold for a bearish signal.
Key Financial Metrics
Key Facts
- General Counsel sold 53.4K shares at $2.39 for $128K on 2026-11-05 (open-market, no 10b5-1 plan)
- See Remarks insider sold 4.9K shares at $2.33 for $11K on 2026-11-09 (open-market, no 10b5-1 plan)
- Total open-market sales: $139K, representing 0.05% of $272M market cap
- Sales occurred 1-7 days before the Q3 2026 earnings release on 2026-11-12
- Q3 2026 earnings reported cash of $279.4M, commercial readiness for KRESLADI, and FDA alignment on Danon disease pivotal trial
Financial Impact
Total insider sales of $139K, well under 0.1% of market cap
Risk Factors
- Small insider sales could be for personal liquidity; no 10b5-1 plan disclosed
- No C-suite (CEO/CFO) selling, reducing signal strength
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1794527071727 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Viewing Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers